$CBBT get ready!! FDA Approval comin IMO https://
Post# of 37039
(Total Views: 208)
Posted On: 11/12/2018 2:33:40 PM
$CBBT get ready!! FDA Approval comin IMO
https://www.businesswire.com/news/home/201605...art-Orange
Cerebain Biotech Announces Business Relocation into the Heart of Orange County, California
May 04, 2016 08:17 AM Eastern Daylight Time
DALLAS--(BUSINESS WIRE)--Cerebain Biotech (OTCQB: CBBT) today announced that it is relocating its corporate headquarters from Dallas, Texas into the heart of Orange County in Costa Mesa, California. The decision to relocate was driven by the Company’s plan to seek FDA approval for its medical device for the treatment of Alzheimer’s and Dementia.
“This move allows us to take advantage of Southern California's strong talent pool and cost-effective environment to continue to build our novel, high-value medical device”
Tweet this
“This move allows us to take advantage of Southern California's strong talent pool and cost-effective environment to continue to build our novel, high-value medical device,” said Eric Clemons, President and CEO of Cerebain. We want to be at the center of an ecosystem that shares our aspirations. Southern California attracts a diverse, technologically-fluent workforce focused on solving challenges for the world. We are excited to bring our headquarters to this dynamic and creative area.”
Cerebain Biotech has been considering the composition and location of its headquarters for more than a year. The Company began its formal review in July 2015, with a list of a number of potential locations. Costa Mesa was selected after a careful evaluation of its location in Southern California, the business ecosystem, talent, long-term costs, quality of life for employees, connections with the world and proximity to other important company assets.
About Cerebain Biotech Corp.
Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations.
https://www.businesswire.com/news/home/201605...art-Orange
Cerebain Biotech Announces Business Relocation into the Heart of Orange County, California
May 04, 2016 08:17 AM Eastern Daylight Time
DALLAS--(BUSINESS WIRE)--Cerebain Biotech (OTCQB: CBBT) today announced that it is relocating its corporate headquarters from Dallas, Texas into the heart of Orange County in Costa Mesa, California. The decision to relocate was driven by the Company’s plan to seek FDA approval for its medical device for the treatment of Alzheimer’s and Dementia.
“This move allows us to take advantage of Southern California's strong talent pool and cost-effective environment to continue to build our novel, high-value medical device”
Tweet this
“This move allows us to take advantage of Southern California's strong talent pool and cost-effective environment to continue to build our novel, high-value medical device,” said Eric Clemons, President and CEO of Cerebain. We want to be at the center of an ecosystem that shares our aspirations. Southern California attracts a diverse, technologically-fluent workforce focused on solving challenges for the world. We are excited to bring our headquarters to this dynamic and creative area.”
Cerebain Biotech has been considering the composition and location of its headquarters for more than a year. The Company began its formal review in July 2015, with a list of a number of potential locations. Costa Mesa was selected after a careful evaluation of its location in Southern California, the business ecosystem, talent, long-term costs, quality of life for employees, connections with the world and proximity to other important company assets.
About Cerebain Biotech Corp.
Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations.
(0)
(0)Scroll down for more posts ▼